Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

Recent News

Melflufen-Based Combination Therapy for Resistant Myeloma
Combination Therapy With Selinexor, Lenalidomide, and Dexamethasone in Resistant Myeloma
Orphan Drug Designation Granted to Immunotherapy for Multiple Myeloma
ESMO 2019: First-Line Versus Non–First-Line Bortezomib in Asian Patients With Myeloma
IMW 2019: Bortezomib-Based Regimens in Newly Diagnosed Multiple Myeloma
SOHO 2019: Are Real-World and Clinical Data Synchronized With Treatment of Resistant Myeloma?
Daratumumab Combination Approved for Transplant-Eligible Patients With Multiple Myeloma
SOHO 2019: Is Minimal Residual Disease Testing Ready for Prime Time?
IMW 2019: Daratumumab-Based Therapy Improves Response in Newly Diagnosed Myeloma
SOHO 2019: Update on the Future of Induction Therapy in Multiple Myeloma
Pilot Study of Ixazomib Plus Dexamethasone in High-Risk Smoldering Myeloma
Quality Care 2019: Program Hastens Start of Bone-Modifying Agents in Myeloma
Assessing Risk of Immunomodulatory Drug–Related Blood Clots in Patients With Multiple Myeloma
Early Research Steps in Understanding APOBEC3B in Myeloma
Early-Stage Clinical Study of Novel BCMA CAR T-Cell Therapy in Resistant Myeloma
Left Ventricular Diastolic Function and Carfilzomib-Induced Cardiovascular Events
Moving Mountains for Multiple Myeloma: Hiking Through Iceland
Does Depression Affect Survival Outcomes in Patients With Multiple Myeloma?
Treatment Outcomes for Patients With t(11;14) Translocation Multiple Myeloma
Subcutaneous Versus Intravenous Daratumumab in Resistant Multiple Myeloma
Novel Monoclonal Antibody Under Study in Resistant Multiple Myeloma
Updated ELOQUENT Data Support Elotuzumab Combination Regimen in Myeloma
Autologous Stem Cell Transplantation: Patient and Caregiver Quality of Life
FDA Accepts Biologics License Application for Isatuximab in Resistant Multiple Myeloma
EHA24 Congress: Selinexor With Daratumumab and Dexamethasone in Resistant Myeloma
FDA Grants Accelerated Approval to Selinexor Combination for Resistant Myeloma
Addition of Isatuximab to Pomalidomide/Dexamethasone in Multiple Myeloma
Partial Clinical Hold Lifted by FDA on Venetoclax Study in Multiple Myeloma
FDA Approves Daratumumab Combination for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
EHA24 Congress: Melflufen Combination Regimen for Resistant Multiple Myeloma
ICML 2019: Is Triplet Induction Therapy Safe for Older Patients With Multiple Myeloma?
EHA24 Congress: Novel Agent Under Study in Combination Therapies for Myeloma
EHA24 Congress: Daratumumab Plus Standard Therapy in Newly Diagnosed Myeloma
EHA24 Congress: Venetoclax Combination Therapy in Resistant Myeloma
ASCO 2019: Adding Daratumumab to Standard of Care in Transplant-Eligible Newly Diagnosed Myeloma
Daratumumab Combination Therapy Granted Priority Review in Multiple Myeloma
ASCO 2019: Predicting Early Relapse in Patients With Myeloma Treated With Triplet Regimens
ASCO 2019: Impact of Insurance Type on Survival in Multiple Myeloma
ECT-001 Granted Regenerative Medicine Advanced Therapy Designation for Treatment of Hematologic Malignancies
Evaluating Adherence to Immunomodulatory Drugs in Multiple Myeloma
FDA Grants Fast Track Designation for CLR 131 in Multiple Myeloma
ASCO 2019: Lenalidomide vs. Observation in Smoldering Multiple Myeloma
Immunoglobulin Lambda Translocation and Treatment Resistance in Multiple Myeloma
Multiple Myeloma Research Foundation Launches Investment Fund to Advance New Therapies


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.